treat hormone-responsive cancers – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:47 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg treat hormone-responsive cancers – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Leuprorelin Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-leuprorelin-market-2021-2025/ Tue, 08 Jun 2021 05:56:53 +0000 https://www.cri-report.com/?post_type=product&p=11759 According to CRI’s market research, the sales value of Leuprorelin in the Chinese market increased rapidly year by year from 2016 to 2019.

The post Investigation Report on China’s Leuprorelin Market 2021-2025 first appeared on CRI Report.

]]> Leuprolide is a synthetic gonadotropin drug used to treat hormone-responsive cancers such as prostate cancer and breast cancer. It can also be used to treat precocious puberty and prevent premature ovulation during in vitro fertilization. Leuprolide was patented in 1973 and approved for medical use in the United States in 1985. In 1992, it obtained the license for importing medicine from China. By the first half of 2021, the manufactures in China’s leuprolide market are Takeda Pharmaceutical Co., Ltd., Shanghai Livzon Pharmaceutical Co., Ltd., and Beijing Biote Pharmaceutical Co., Ltd.

According to CRI’s market research, the sales value of Leuprorelin in the Chinese market increased rapidly year by year from 2016 to 2019. Due to the impact of the COVID-19 epidemic on the hospital’s overall diagnosis and treatment services, the growth rate of sales value decreased from 21.01% in 2019 to 11.11% in 2020. The sales value of Leuprorelin in the Chinese market reached CNY1108 million in 2020 and the CAGR was 15.1% from 2016 to 2020.

CRI expects that with the alleviation of the COVID-19 epidemic, sales of Leuprorelin will have restorative growth from 2021 to 2025. On August 10, 2020, Shanghai-Takeda China announced that its 3-month dosage form (specification: 11.25mg) of Innate was officially approved by the China National Medical Products Administration for the treatment of Central Precocious Puberty (CPP). This is the third indication approved in China for the 3-month dosage form of Innate. The sales volume of leuprolide is expected to increase with the increase in the number of indications, and there is room for sales to increase.

Topics Covered:
-The impact of COVID-19 on China’s Leuprorelin market
– Sales value of China’s Leuprorelin 2016-2020
– Competitive landscape of China’s Leuprorelin market
– Prices of Leuprorelin in China
– Prices of Leuprorelin in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Leuprorelin market
– Prospect of China’s Leuprorelin market from 2021 to 2025

The post Investigation Report on China’s Leuprorelin Market 2021-2025 first appeared on CRI Report.

]]>